申联生物(688098) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 was CNY 30,341.47 million, a slight increase of 0.64% compared to CNY 30,148.71 million in 2023[24]. - The net profit attributable to shareholders for 2024 was CNY -4,474.01 million, representing a significant decrease of 241.95% from CNY 3,151.87 million in 2023[24]. - The net cash flow from operating activities increased dramatically to CNY 8,936.20 million, up 2,434.71% from CNY 352.55 million in 2023[24]. - The basic earnings per share for 2024 was CNY -0.11, a decrease of 237.5% from CNY 0.08 in 2023[25]. - The weighted average return on equity decreased to -3.07% in 2024, down 5.19 percentage points from 2.12% in 2023[25]. - The company achieved operating revenue of 303.41 million yuan, a year-on-year increase of 0.64%[148]. - The net profit attributable to shareholders was -44.74 million yuan, a year-on-year decrease of 241.95%[148]. - Operating costs increased by 37.16% to 120.61 million yuan compared to the previous year[149]. - Research and development expenses rose by 10.84% to 49.36 million yuan, reflecting an expansion of the R&D team[149]. - The gross margin for the main business decreased by 10.7 percentage points to 60.12%[152]. Research and Development - Research and development expenses accounted for 28.34% of operating revenue in 2024, an increase of 4.94 percentage points from 23.4% in 2023[25]. - The company invested 85.99 million yuan in R&D in 2024, with 28 national patents filed and 2 new veterinary drug registration certificates obtained[36]. - The company has established five major technology platforms: inactivated vaccine technology, synthetic peptide vaccine technology, virus-like particle vaccine technology, nucleic acid (mRNA) technology, and in vitro diagnostic technology[113]. - The company has increased R&D investment, with total R&D expenditures reaching ¥85,992,438.63, a 21.88% increase from the previous year, and R&D expenditures as a percentage of revenue rising to 28.34%[105]. - The company has applied for 28 new patents this year, including 8 invention patents, bringing the total number of patents to 146, with 85 granted[103]. - The company is focusing its R&D resources on key projects to enhance its competitive edge in disease prevention products[185]. - The company is actively working on new product launches and market expansion, but market promotion of new products has been affected by a complex market environment[136]. Product Development and Innovation - The company has developed proprietary technologies such as i-Molsta for vaccine antigen stabilization and i-Nada for efficient vaccine adjuvant technology, showcasing innovation in product development[14]. - The company is advancing the development of new vaccine projects, including circular RNA vaccines and genetically engineered subunit vaccines, to enhance its competitive edge in the market[26]. - The company is focusing on the development of multivalent vaccines and gene-engineered vaccines to reduce the number of vaccinations required for immunized animals, thereby alleviating the burden on farmers[84]. - The company has established a virus-like particle (VLP) vaccine technology platform that supports the development of multi-valent vaccines, having completed rapid construction and scale-up production technology for major categories of VLPs, including foot-and-mouth disease virus and rotavirus[96]. - The mRNA vaccine technology platform has made key progress, with the completion of core technology platforms for mRNA design and production, enabling the company to produce core raw materials independently, which is crucial for efficient vaccine development and cost control[98]. - The company is actively researching and developing new adjuvants, particularly water-based adjuvants, to enhance vaccine efficacy and safety[86]. - The company has successfully developed and optimized the process for the inactivated vaccine for bovine nodular dermatitis, which shows improved immunization effects[92]. Market and Sales Strategy - The company is focusing on large-scale breeding groups and provincial pig farms to enhance brand influence and product recognition[60]. - The company is enhancing its marketing system to focus on large-scale breeding groups, integrating marketing, R&D, and service functions to improve customer satisfaction[42]. - The company is actively expanding into the pet market, developing high-quality biological products to meet increasing demand[66]. - The company is implementing a "three-step overseas expansion model" targeting Southeast Asia, Central Asia, South America, and Africa to meet the demand for animal vaccines[46]. - The company is expanding its ruminant vaccine portfolio, with key breakthroughs in the development of vaccines for bovine viral diarrhea and ovine cysticercosis[38]. - The company is actively expanding its overseas market by leveraging advanced biopharmaceutical technology platforms and capital operation tools, focusing on human innovative drugs[46]. Governance and Compliance - The company has a standard unqualified audit report from Rongcheng Accounting Firm, ensuring the accuracy and completeness of its financial statements[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, reflecting good governance practices[9]. - The company has strict compliance with GMP regulations, but potential risks exist regarding the renewal of necessary production licenses and permits[137]. - The company maintains a controllable biosecurity risk status, having passed the biosecurity level three acceptance, but must adhere to strict management to avoid potential biosecurity hazards[138]. - The company is committed to environmental protection but faces risks related to stricter national environmental standards that could impact its operations and reputation[140]. Risks and Challenges - The company has identified significant risk factors in its management discussion, which investors are advised to review carefully[5]. - The company is facing risks of significant performance decline due to intensified competition in the animal health industry, leading to decreased product prices and increased operational costs[132]. - The company faces risks related to accounts receivable collection due to reliance on government procurement and market sales[142]. - The company is at risk of losing tax benefits if it fails to maintain its status as a high-tech enterprise, which currently allows a reduced corporate income tax rate of 15%[143].